-
In the fast-evolving landscape of biomedical science, function polypeptides have emerged as a game-changer, bridging the gap between genetic information and therapeutic application. These engineered peptide sequences offer high specificity, stability, and bioactivity, making them ideal candidates for pharmaceutical, cosmetic, and diagnostic purposes.
-
On April 16, 2025, the U.S. FDA released the latest Drug Master File (DMF) list. Xiushi Biopharma's Semaglutide product, produced with a breakthrough bioprocess, successfully made the list (DMF number: 041460). This milestone achievement not only demonstrates Xiushi Biopharma's innovative strength b
-
In recent years, the development of peptide-based drugs has witnessed remarkable progress, especially with the success of modified peptides like Semaglutide and Tirzepatide.
-
In recent years, peptide-based therapeutics have taken center stage in the pharmaceutical industry. Their high specificity, low toxicity, and proven clinical effectiveness have made peptides an essential component in the development of treatments for metabolic disorders, cancer, infectious diseases, and beyond.
-
In the fast-paced world of biotech innovation, time, quality, and cost-efficiency are paramount. Early-stage companies and research-driven startups often operate with limited resources, tight timelines, and considerable uncertainty.
